Feed - News and features
https://pharmaphorum.com/
enFri, 20 Jun 2025 09:16:43 +0000Fri, 20 Jun 2025 08:30:22 +0000Could a Novo error set up early GLP-1 generics in Canada?
https://pharmaphorum.com/news/could-novo-error-set-early-glp-1-generics-canada
Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.Phil.Taylorhttps://pharmaphorum.com/news/could-novo-error-set-early-glp-1-generics-canada2025-06-20T08:30:22+0000
Feed - News and features
Dismay but little surprise as NICE rejects Alzheimer's drugs
https://pharmaphorum.com/news/dismay-little-surprise-nice-rejects-alzheimers-drugs
Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.Phil.Taylorhttps://pharmaphorum.com/news/dismay-little-surprise-nice-rejects-alzheimers-drugs2025-06-19T07:38:12+0000
Feed - News and features
Gilead's twice-yearly PrEP drug is cleared by FDA
https://pharmaphorum.com/news/gileads-twice-yearly-prep-drug-cleared-fda
Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?Phil.Taylorhttps://pharmaphorum.com/news/gileads-twice-yearly-prep-drug-cleared-fda2025-06-18T21:03:33+0000
Feed - News and features
Amid sector disruption, biotech must focus on 'fundamentals'
https://pharmaphorum.com/news/amid-sector-disruption-biotech-must-focus-fundamentals
The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.Phil.Taylorhttps://pharmaphorum.com/news/amid-sector-disruption-biotech-must-focus-fundamentals2025-06-18T17:18:06+0000
Feed - News and features
Biogen bids to extend use of Skyclarys to younger patients
https://pharmaphorum.com/news/biogen-bids-extend-use-skyclarys-younger-patients
Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.Phil.Taylorhttps://pharmaphorum.com/news/biogen-bids-extend-use-skyclarys-younger-patients2025-06-18T14:49:25+0000
Feed - News and features